Developer docs
API playgroundTry for free, no card

Search company profiles

Ibex Medical Analytics

Full company profile

uuid00038fu

Namestring
Ibex Medical Analytics
Legal namestring
Ibex Medical Analytics Ltd.
Websiteurl
ibex-ai.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Ibex Medical Analytics, founded in 2016 in Tel Aviv, develops AI-powered clinical-grade diagnostic solutions for pathology. Its core platform, currently branded Galen and most recently released as Ibex 4 in March 2026, ingests whole slide images of tissue specimens and applies deep-learning computer vision models to detect, grade, and classify cancers across multiple tissue types (breast, prostate, gastric) and staining modalities (H&E plus IHC for HER2, ER, PR, Ki67). Models are trained on a curated dataset of over 10 million slides with 150,000+ annotations from expert pathologists and validated through peer-reviewed publications in journals including Nature, Lancet Digital Health and the Journal of Clinical Oncology. The company holds the first FDA 510(k) clearance for an AI prostate-cancer detection device (February 2025) and CE-IVDR certifications across multiple products, with regulatory registrations covering the US, UK, EU, Australia, Brazil, Israel and Switzerland.

The product line spans Ibex Breast (with HER2, ER/PR, Ki67 and emerging Lymph Node modules), Ibex Prostate (Detect and grading variants), and Ibex Gastric, alongside a Biopharma Services arm providing biomarker quantification, companion diagnostic development, and clinical trial optimization for pharmaceutical partners including AstraZeneca, Daiichi Sankyo and Roche. Revenue is generated primarily through enterprise SaaS subscriptions, quote-based site licenses, and biopharma service agreements, with deployment options across cloud, on-premise, hybrid, and air-gapped environments. Go-to-market is direct enterprise field sales to laboratory networks and health systems (50+ deployed globally including HNL Lab Medicine, PathGroup, Alverno, Unilabs, CorePlus, NHS Wales, Institut Curie, UPMC, Maccabi Healthcare Services, and Dr. Lal Path Labs) supplemented by channel and integration partnerships with digital pathology vendors (Philips, Roche, Proscia, Fujifilm, Sectra, Dedalus, Indica Labs, Leica Biosystems, PathPresenter, mTuitive, and others). Reported 2024 ARR is $15.8 million, with the company citing a 70%+ increase in customer base and doubling of case volume in 2025, alongside total funding of over $100 million across Series B and Series C rounds plus debt financing.

Short descriptiontext

Ibex Medical Analytics develops AI-powered, clinical-grade diagnostic software for pathologists, analyzing whole slide images to detect, grade, and quantify breast, prostate, and gastric cancers. It sells enterprise subscriptions and biopharma services to reference laboratories, health systems, and pharmaceutical partners across more than 50 deployments globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBrookline, United States
HQ citystring
Brookline
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI-powered cancer diagnostics, digital pathology platform, biomarker quantification, clinical decision support, whole slide imaging
Industry2 codes
PRIMARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
NAICS code3 codes
  • Medical and Diagnostic Laboratories62151
  • Software Publishers513210
  • Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services518210
SIC code3 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Surgical & Medical Instruments & Apparatus3841
  • Services-Medical Laboratories8071
Product category
AI-powered Digital Pathology Diagnostics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1AI-Powered Diagnostics Platform Subscription
TypeSubscription Recurring
Description

SaaS-based subscription model providing access to Ibex's clinical-grade AI pathology platform, including algorithm updates, technical support, and integration services. Deployed across laboratory networks and healthcare systems on a per-analysis or site license basis.

getlatka.com
2Biopharma Services
TypeSubscription Recurring
Description

Partnership services for pharmaceutical companies including biomarker development, clinical trial optimization, and companion diagnostic program support. Spans from exploratory preclinical work through regulatory submissions and global commercialization.

businesswire.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Operations
Pricing details1 tier
1Enterprise site license
ModelSubscriptionBilling cadenceAnnual
Notes

Quote-based pricing for laboratory networks and healthcare systems. Multiple deployment options including cloud-based, on-premise, hybrid, and air-gapped environments.

ibex-ai.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Ibex Medical Analytics develops and sells clinical-grade AI software that analyzes digitized pathology slides to detect, grade, and classify cancer and quantify biomarkers in breast, prostate, and gastric tissue. The platform (Galen / Ibex 4) is sold as an enterprise subscription to hospital pathology departments, reference laboratories, and biopharmaceutical companies, with deployments across cloud, on-premise, hybrid, and air-gapped environments.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 37% productivity gain and 27% reduction in diagnosis time for prostate cancer diagnosis
+7 more records
Product overview1 text field

Ibex Medical Analytics offers a unified AI-powered pathology platform (Galen) comprising multiple clinically deployed solutions for cancer diagnostics. The core platform supports breast, prostate, and gastric cancers across H&E and IHC workflows. Key products include Ibex Breast (with HER2, ER/PR, Ki67 IHC sub-modules and Lymph Node under development), Ibex Prostate (FDA-cleared February 2025 with Detect sub-module), and Ibex Gastric (CE-marked). The Ibex 4 platform released March 2026 provides the next-generation end-to-end workflow with zero-click IHC quantification. Biopharma Services extends the platform for biomarker development, companion diagnostics, and clinical trial support with partnerships including Roche and AstraZeneca/Daiichi Sankyo. Deployed across over 50 health systems worldwide.

Product and service7 records
1Ibex 4 (Galen Platform)
CategoryAI Pathology Platform
Description

Next-generation AI-powered pathology platform providing end-to-end cancer diagnostics for breast, prostate, and gastric cancers. Features automated H&E analysis, zero-click IHC quantification for HER2, ER, PR, and Ki67, enhanced user interface with prioritized insights, and streamlined LIS integration for clinical-grade cancer pathology in routine use.

2Ibex Breast Suite
CategoryAI Breast Cancer Diagnostics
Description

AI-powered breast cancer diagnostics suite for H&E and IHC analysis on biopsies and excisions. Detects over 50 malignant and benign tissue morphologies including microinvasion, DCIS, LVI, IDC vs ILC, and supports automated HER2, ER/PR, and Ki67 quantification aligned with ASCO/CAP guidelines; reduces review times up to 43%.

3Ibex Breast HER2
CategoryAI Breast IHC Quantification
Description

AI-powered HER2 biomarker scoring solution that automates 2023 ASCO/CAP scoring guidelines, removing subjectivity for HER2, HER2-low, and HER2-ultralow cases. Features zero-click invasive tumor detection, automated cell identification, interactive contours, and score recalculation.

4Ibex Prostate
CategoryAI Prostate Cancer Diagnostics
Description

Clinical-grade AI solution assisting pathologists in detecting and grading prostate cancer in core needle biopsies and TURP specimens. Demonstrates AUC 0.991, 98.4% sensitivity, supports Gleason grading, tumor sizing, and perineural invasion detection, delivering 37% productivity gain and 27% reduction in diagnosis time.

5Ibex Prostate Detect
CategoryAI Prostate Cancer Detection Device
Description

FDA 510(k)-cleared AI device for identifying missed prostatic cancers in whole slide images of core needle biopsies. Demonstrated 99.6% accuracy rate and identified 13% previously missed cancers in validated studies; first FDA-cleared product from Ibex.

6Ibex Gastric
CategoryAI Gastric Cancer Diagnostics
Description

AI-powered solution for gastric cancer detection and gastrointestinal cancer diagnostics. Assists pathologists in detecting gastric cancer, dysplasia, H. pylori, and lymphomas; CE-marked under IVDR and used in everyday clinical practice.

7Biopharma Services
CategoryBiopharma Services
Description

AI-powered biomarker development, clinical-trial optimization, and companion-diagnostic services for pharmaceutical partners. Spans exploratory preclinical work through regulatory submissions to global commercialization, including HER2 quantification, tumor microenvironment analysis, and ADC biomarker development.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration on AI-powered digital pathology applications for improved patient care, integrating Ibex's AI with Roche's pathology solutions and navify Digital Pathology marketplace. Also collaborated with AWS on joint AI deployment.

Strategic tierCoreTypeTechnology or Integration
Description

Expanded partnership to enhance AI-enabled pathology workflows. Philips integration enables Ibex AI deployment across Philips' digital pathology customer base, improving workflow productivity by 37%.

Strategic tierCoreTypeTechnology or Integration
Description

Integration of Ibex AI into Proscia's Concentriq image management platform, enabling joint customers to deploy AI-powered cancer diagnostics within existing digital pathology workflows.

Strategic tierCoreTypeTechnology or Integration
Description

Launched end-to-end AI-powered digital pathology solution across Europe, combining Dedalus' laboratory information systems with Ibex's AI diagnostics capabilities.

Strategic tierCoreTypeTechnology or Integration
Description

Partnership to integrate Ibex's AI platform with Fujifilm's pathology solutions to improve cancer diagnostics and reduce turnaround times globally.

Strategic tierCoreTypeTechnology or Integration
Description

Strategic partnership integrating Ibex's AI-powered cancer diagnostic intelligence with mTuitive's CAP-, RCPath-, and ICCR-compliant structured reporting platform for automated population of AI findings into standardized reports.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Clinical deployment partnership for AI-powered prostate cancer diagnostics including TURP procedures. CorePlus surpassed 250,000 AI-based analyses in routine practice. First laboratory in Americas to deploy AI for prostate and breast biopsies.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Strategic collaboration to deploy Ibex's AI solutions for prostate cancer diagnostics, integrating AI into HNL Lab Medicine's existing digital pathology infrastructure built on Proscia's Concentriq platform and Leica Biosystems imaging.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Partnership to expand use of AI-powered cancer diagnosis platform across Alverno's 32 laboratories to improve diagnosis of breast and prostate cancers.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Strategic partnership for clinical deployment of AI-powered pathology solutions across PathGroup's diagnostic network.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration on AI-based HER2 scoring product development, validation, and clinical adoption. IVDR certification obtained for HER2 biomarker scoring solution validated with AstraZeneca and Daiichi Sankyo. Strategic partnership for precision medicine initiatives.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration on HER2 biomarker scoring solution validation, supporting development of AI-powered companion diagnostics for targeted therapies.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

PathAI is a direct competitor developing AI-powered pathology solutions for cancer diagnostics across multiple tissue types. Both companies offer deep-learning algorithms for H&E and IHC analysis, partner with biopharma for biomarker development, and compete for the same pathology lab and health system customers.

TypeDirect peer
Description

Paige is a direct competitor in AI-driven digital pathology with FDA-authorized products for prostate cancer detection. Both target pathology laboratories and biopharma customers, leverage deep learning on whole slide images, and pursue similar regulatory and OEM partnership strategies globally.

TypeDirect peer
Description

Owkin applies AI to pathology and clinical research with a strong biopharma orientation. Both Ibex and Owkin compete in AI-assisted cancer detection and biopharma biomarker/companion diagnostic programs, and target pharmaceutical partners for translational research and clinical trial optimization.

TypeEmerging player
Description

Proscia is a digital pathology platform provider that integrates third-party AI algorithms including Ibex's. While partly a partner (Concentriq IMS), Proscia also develops its own AI applications and competes for the same laboratory platform spend, making it an adjacent competitor as well as a distribution channel.

TypeBroad incumbent
Description

Philips is both a key OEM partner and a broad incumbent in digital pathology with scanners, image management systems, and workflow software. Philips competes at the platform layer and could vertically integrate AI capabilities, creating both partnership upside and channel conflict for Ibex.

TypeBroad incumbent
Description

Roche is a strategic partner (navify Digital Pathology collaboration with AWS) but also a broad incumbent with scanner hardware, uPath software, and internal AI initiatives through Roche Diagnostics. Roche has the scale to bundle competing AI, representing both upside and a competitive threat to Ibex.

TypeBroad incumbent
Description

Fujifilm is a digital pathology OEM partner and broad incumbent with scanners and pathology workflow software globally. Like Philips and Roche, Fujifilm can either distribute Ibex AI or develop competing algorithms, making it both a partner and a structural competitor.

TypeEmerging player
Description

AIRA Matrix is an emerging AI pathology player focused on cancer diagnostics and workflow automation for pathology labs in India and emerging markets. It is comparable as an AI pathology specialist serving diagnostic labs but operates at smaller scale than Ibex.

TypeEmerging player
Description

Mindpeak develops AI image analysis solutions for pathology, including IHC quantification and H&E analysis. It competes in similar IHC biomarker workflows (HER2, Ki67, PD-L1) and serves pharmaceutical and clinical customers in Europe.

10Aignostics
TypeEmerging player
Description

Aignostics is an AI pathology company spun out of Charité Berlin focused on biomarker discovery and companion diagnostics for biopharma. It overlaps with Ibex's biopharma services and translational research offerings while representing an emerging competitor in precision medicine AI.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers15 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration5 records

Each record includes

Title, Type, Description, Source

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles24 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance12 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ibex Medical Analytics

AI-powered Digital Pathology Diagnosticsibex-ai.com

Ibex Medical Analytics develops AI-powered, clinical-grade diagnostic software for pathologists, analyzing whole slide images to detect, grade, and quantify breast, prostate, and gastric cancers. It sells enterprise subscriptions and biopharma services to reference laboratories, health systems, and pharmaceutical partners across more than 50 deployments globally.

What Ibex Medical Analytics does

Ibex Medical Analytics, founded in 2016 in Tel Aviv, develops AI-powered clinical-grade diagnostic solutions for pathology. Its core platform, currently branded Galen and most recently released as Ibex 4 in March 2026, ingests whole slide images of tissue specimens and applies deep-learning computer vision models to detect, grade, and classify cancers across multiple tissue types (breast, prostate, gastric) and staining modalities (H&E plus IHC for HER2, ER, PR, Ki67). Models are trained on a curated dataset of over 10 million slides with 150,000+ annotations from expert pathologists and validated through peer-reviewed publications in journals including Nature, Lancet Digital Health and the Journal of Clinical Oncology. The company holds the first FDA 510(k) clearance for an AI prostate-cancer detection device (February 2025) and CE-IVDR certifications across multiple products, with regulatory registrations covering the US, UK, EU, Australia, Brazil, Israel and Switzerland.

The product line spans Ibex Breast (with HER2, ER/PR, Ki67 and emerging Lymph Node modules), Ibex Prostate (Detect and grading variants), and Ibex Gastric, alongside a Biopharma Services arm providing biomarker quantification, companion diagnostic development, and clinical trial optimization for pharmaceutical partners including AstraZeneca, Daiichi Sankyo and Roche. Revenue is generated primarily through enterprise SaaS subscriptions, quote-based site licenses, and biopharma service agreements, with deployment options across cloud, on-premise, hybrid, and air-gapped environments. Go-to-market is direct enterprise field sales to laboratory networks and health systems (50+ deployed globally including HNL Lab Medicine, PathGroup, Alverno, Unilabs, CorePlus, NHS Wales, Institut Curie, UPMC, Maccabi Healthcare Services, and Dr. Lal Path Labs) supplemented by channel and integration partnerships with digital pathology vendors (Philips, Roche, Proscia, Fujifilm, Sectra, Dedalus, Indica Labs, Leica Biosystems, PathPresenter, mTuitive, and others). Reported 2024 ARR is $15.8 million, with the company citing a 70%+ increase in customer base and doubling of case volume in 2025, alongside total funding of over $100 million across Series B and Series C rounds plus debt financing.

Ibex Medical Analytics firmographics

Firmographics
Name
Ibex Medical Analytics
Legal name
Ibex Medical Analytics Ltd.
Website
https://ibex-ai.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
51–100 employees
Short description
Ibex Medical Analytics develops AI-powered, clinical-grade diagnostic software for pathologists, analyzing whole slide images to detect, grade, and quantify breast, prostate, and gastric cancers. It sells enterprise subscriptions and biopharma services to reference laboratories, health systems, and pharmaceutical partners across more than 50 deployments globally.
Ownership category
akta.pro rank

Ibex Medical Analytics industry classification

Industry
Product category
AI-powered Digital Pathology Diagnostics
NAICS
Medical and Diagnostic Laboratories (62151), Software Publishers (513210), Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (518210)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)

Keywords

  • AI-powered cancer diagnostics
  • Digital pathology platform
  • Biomarker quantification
  • Clinical decision support
  • Whole slide imaging

Where Ibex Medical Analytics is headquartered

Location

Headquarters

HQ city
Brookline
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Ibex Medical Analytics business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Operations

Revenue model

  1. AI-Powered Diagnostics Platform Subscription: SaaS-based subscription model providing access to Ibex's clinical-grade AI pathology platform, including algorithm updates, technical support, and integration services. Deployed across laboratory networks and healthcare systems on a per-analysis or site license basis.
  2. Biopharma Services: Partnership services for pharmaceutical companies including biomarker development, clinical trial optimization, and companion diagnostic program support. Spans from exploratory preclinical work through regulatory submissions and global commercialization.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise site license

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Ibex Medical Analytics product offering

Product offering

Core offering

Ibex Medical Analytics develops and sells clinical-grade AI software that analyzes digitized pathology slides to detect, grade, and classify cancer and quantify biomarkers in breast, prostate, and gastric tissue. The platform (Galen / Ibex 4) is sold as an enterprise subscription to hospital pathology departments, reference laboratories, and biopharmaceutical companies, with deployments across cloud, on-premise, hybrid, and air-gapped environments.

Product overview

Ibex Medical Analytics offers a unified AI-powered pathology platform (Galen) comprising multiple clinically deployed solutions for cancer diagnostics. The core platform supports breast, prostate, and gastric cancers across H&E and IHC workflows. Key products include Ibex Breast (with HER2, ER/PR, Ki67 IHC sub-modules and Lymph Node under development), Ibex Prostate (FDA-cleared February 2025 with Detect sub-module), and Ibex Gastric (CE-marked). The Ibex 4 platform released March 2026 provides the next-generation end-to-end workflow with zero-click IHC quantification. Biopharma Services extends the platform for biomarker development, companion diagnostics, and clinical trial support with partnerships including Roche and AstraZeneca/Daiichi Sankyo. Deployed across over 50 health systems worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

  • Ibex 4 (Galen Platform) Next-generation AI-powered pathology platform providing end-to-end cancer diagnostics for breast, prostate, and gastric cancers. Features automated H&E analysis, zero-click IHC quantification for HER2, ER, PR, and Ki67, enhanced user interface with prioritized insights, and streamlined LIS integration for clinical-grade cancer pathology in routine use.
  • Ibex Breast Suite AI-powered breast cancer diagnostics suite for H&E and IHC analysis on biopsies and excisions. Detects over 50 malignant and benign tissue morphologies including microinvasion, DCIS, LVI, IDC vs ILC, and supports automated HER2, ER/PR, and Ki67 quantification aligned with ASCO/CAP guidelines; reduces review times up to 43%.
  • Ibex Breast HER2 AI-powered HER2 biomarker scoring solution that automates 2023 ASCO/CAP scoring guidelines, removing subjectivity for HER2, HER2-low, and HER2-ultralow cases. Features zero-click invasive tumor detection, automated cell identification, interactive contours, and score recalculation.
  • Ibex Prostate Clinical-grade AI solution assisting pathologists in detecting and grading prostate cancer in core needle biopsies and TURP specimens. Demonstrates AUC 0.991, 98.4% sensitivity, supports Gleason grading, tumor sizing, and perineural invasion detection, delivering 37% productivity gain and 27% reduction in diagnosis time.
  • Ibex Prostate Detect FDA 510(k)-cleared AI device for identifying missed prostatic cancers in whole slide images of core needle biopsies. Demonstrated 99.6% accuracy rate and identified 13% previously missed cancers in validated studies; first FDA-cleared product from Ibex.
  • Ibex Gastric AI-powered solution for gastric cancer detection and gastrointestinal cancer diagnostics. Assists pathologists in detecting gastric cancer, dysplasia, H. pylori, and lymphomas; CE-marked under IVDR and used in everyday clinical practice.
  • Biopharma Services AI-powered biomarker development, clinical-trial optimization, and companion-diagnostic services for pharmaceutical partners. Spans exploratory preclinical work through regulatory submissions to global commercialization, including HER2 quantification, tumor microenvironment analysis, and ADC biomarker development.

Quantifiable outcome

  • 37% productivity gain and 27% reduction in diagnosis time for prostate cancer diagnosis
  • +7 more outcomes

Companies that use Ibex Medical Analytics

Customer profile

Named customers15 records

Segments3 records

Ideal customer profiles2 records

Ibex Medical Analytics technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability6 records

Feature6 records

Ibex Medical Analytics partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core.

  • RochecoreStrategic or Co-development PartnerCollaboration on AI-powered digital pathology applications for improved patient care, integrating Ibex's AI with Roche's pathology solutions and navify Digital Pathology marketplace. Also collaborated with AWS on joint AI deployment.
  • PhilipscoreTechnology or IntegrationExpanded partnership to enhance AI-enabled pathology workflows. Philips integration enables Ibex AI deployment across Philips' digital pathology customer base, improving workflow productivity by 37%.
  • ProsciacoreTechnology or IntegrationIntegration of Ibex AI into Proscia's Concentriq image management platform, enabling joint customers to deploy AI-powered cancer diagnostics within existing digital pathology workflows.
  • DedaluscoreTechnology or IntegrationLaunched end-to-end AI-powered digital pathology solution across Europe, combining Dedalus' laboratory information systems with Ibex's AI diagnostics capabilities.
  • Fujifilm Healthcare EuropecoreTechnology or IntegrationPartnership to integrate Ibex's AI platform with Fujifilm's pathology solutions to improve cancer diagnostics and reduce turnaround times globally.
  • mTuitivecoreTechnology or IntegrationStrategic partnership integrating Ibex's AI-powered cancer diagnostic intelligence with mTuitive's CAP-, RCPath-, and ICCR-compliant structured reporting platform for automated population of AI findings into standardized reports.
  • CorePluscoreImplementation/ SI/ Consulting PartnerClinical deployment partnership for AI-powered prostate cancer diagnostics including TURP procedures. CorePlus surpassed 250,000 AI-based analyses in routine practice. First laboratory in Americas to deploy AI for prostate and breast biopsies.
  • HNL Lab MedicinecoreImplementation/ SI/ Consulting PartnerStrategic collaboration to deploy Ibex's AI solutions for prostate cancer diagnostics, integrating AI into HNL Lab Medicine's existing digital pathology infrastructure built on Proscia's Concentriq platform and Leica Biosystems imaging.
  • Alverno LaboratoriescoreImplementation/ SI/ Consulting PartnerPartnership to expand use of AI-powered cancer diagnosis platform across Alverno's 32 laboratories to improve diagnosis of breast and prostate cancers.
  • PathGroupcoreImplementation/ SI/ Consulting PartnerStrategic partnership for clinical deployment of AI-powered pathology solutions across PathGroup's diagnostic network.
  • AstraZenecacoreStrategic or Co-development PartnerCollaboration on AI-based HER2 scoring product development, validation, and clinical adoption. IVDR certification obtained for HER2 biomarker scoring solution validated with AstraZeneca and Daiichi Sankyo. Strategic partnership for precision medicine initiatives.
  • Daiichi SankyocoreStrategic or Co-development PartnerCollaboration on HER2 biomarker scoring solution validation, supporting development of AI-powered companion diagnostics for targeted therapies.

Scale indicators11 records

Recent moves6 records

Expansion highlights7 records

Ibex Medical Analytics competitors and assessment

Company assessment

Direct peers

  • PathAI: PathAI is a direct competitor developing AI-powered pathology solutions for cancer diagnostics across multiple tissue types. Both companies offer deep-learning algorithms for H&E and IHC analysis, partner with biopharma for biomarker development, and compete for the same pathology lab and health system customers.
  • Paige: Paige is a direct competitor in AI-driven digital pathology with FDA-authorized products for prostate cancer detection. Both target pathology laboratories and biopharma customers, leverage deep learning on whole slide images, and pursue similar regulatory and OEM partnership strategies globally.
  • Owkin: Owkin applies AI to pathology and clinical research with a strong biopharma orientation. Both Ibex and Owkin compete in AI-assisted cancer detection and biopharma biomarker/companion diagnostic programs, and target pharmaceutical partners for translational research and clinical trial optimization.

Emerging players

  • Proscia: Proscia is a digital pathology platform provider that integrates third-party AI algorithms including Ibex's. While partly a partner (Concentriq IMS), Proscia also develops its own AI applications and competes for the same laboratory platform spend, making it an adjacent competitor as well as a distribution channel.
  • AIRA Matrix: AIRA Matrix is an emerging AI pathology player focused on cancer diagnostics and workflow automation for pathology labs in India and emerging markets. It is comparable as an AI pathology specialist serving diagnostic labs but operates at smaller scale than Ibex.
  • Mindpeak: Mindpeak develops AI image analysis solutions for pathology, including IHC quantification and H&E analysis. It competes in similar IHC biomarker workflows (HER2, Ki67, PD-L1) and serves pharmaceutical and clinical customers in Europe.
  • Aignostics: Aignostics is an AI pathology company spun out of Charité Berlin focused on biomarker discovery and companion diagnostics for biopharma. It overlaps with Ibex's biopharma services and translational research offerings while representing an emerging competitor in precision medicine AI.

Broad incumbents

  • Philips Digital Pathology: Philips is both a key OEM partner and a broad incumbent in digital pathology with scanners, image management systems, and workflow software. Philips competes at the platform layer and could vertically integrate AI capabilities, creating both partnership upside and channel conflict for Ibex.
  • Roche Digital Pathology: Roche is a strategic partner (navify Digital Pathology collaboration with AWS) but also a broad incumbent with scanner hardware, uPath software, and internal AI initiatives through Roche Diagnostics. Roche has the scale to bundle competing AI, representing both upside and a competitive threat to Ibex.
  • Fujifilm Healthcare Digital Pathology: Fujifilm is a digital pathology OEM partner and broad incumbent with scanners and pathology workflow software globally. Like Philips and Roche, Fujifilm can either distribute Ibex AI or develop competing algorithms, making it both a partner and a structural competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Ibex Medical Analytics social profiles

Digital presence

Ibex Medical Analytics compliance and trust

Trust signal

Compliance12 records

Ibex Medical Analytics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ibex Medical Analytics leadership team

Management profile

Number of profiles

Profiles24 records

Ibex Medical Analytics funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ibex Medical Analytics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ibex Medical Analytics

What does Ibex Medical Analytics do?

Ibex Medical Analytics develops and sells clinical-grade AI software that analyzes digitized pathology slides to detect, grade, and classify cancer and quantify biomarkers in breast, prostate, and gastric tissue. The platform (Galen / Ibex 4) is sold as an enterprise subscription to hospital pathology departments, reference laboratories, and biopharmaceutical companies, with deployments across cloud, on-premise, hybrid, and air-gapped environments.

Is Ibex Medical Analytics a public or private company?

Ibex Medical Analytics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Ibex Medical Analytics founded?

Ibex Medical Analytics was founded in 2016. It employs 51 to 100 people.

Where is Ibex Medical Analytics based?

Ibex Medical Analytics is headquartered in Brookline, United States, in the North America region.

How does Ibex Medical Analytics make money?

Two revenue lines are on record. AI-Powered Diagnostics Platform Subscription is the primary driver. The others are biopharma Services.

Who are Ibex Medical Analytics's main competitors?

Direct peers on record are PathAI, Paige and Owkin. Emerging players are Proscia, AIRA Matrix, Mindpeak and Aignostics. Broad incumbents are Philips Digital Pathology, Roche Digital Pathology and Fujifilm Healthcare Digital Pathology.

Does Ibex Medical Analytics have an API?

Yes. Ibex offers an open API that enables AI insights to integrate into clinical workflows. The platform is interoperable and integrates with third-party digital pathology software solutions, scanning platforms, and laboratory information systems. Specific technical integration details are facilitated through partnerships with LIS, IMS, and WSI scanner vendors.

What industry is Ibex Medical Analytics in?

Ibex Medical Analytics's product category is AI-powered Digital Pathology Diagnostics. Its primary akta.pro industry code is HDAAAEAH, Medical Imaging AI, with a secondary code of HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays). Its NAICS code is 62151 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageIbex Medical Analytics Achieves CE-IVDR Certification for Breast Panel IHCs, Elevating the Standard of Care in AI-Powered Breast Cancer DiagnosticsIbex Medical Analytics announced it has received In Vitro Diagnostic Medical Devices Regulation (IVDR) certification for its Ibex Breast ER, PR and Ki67 immunohistochemistry diagnostic tools. This milestone completes regulatory approval for its entire breast portfolio, which now includes a fully IVDR-certified end-to-end workflow covering H&E, HER2, ER, PR, and Ki67-stained whole slide images for breast cancer diagnostics. The company states this certification enables AI-powered precision in diagnostic testing, with clinical studies showing a 10% improvement in interobserver agreement for Ki67 scoring and 94% accuracy compared to reference expert scores.MorningstarIbex Medical Analytics Achieves CE-IVDR Certification for Breast Panel IHCs, Elevating the Standard of Care in AI-Powered Breast Cancer DiagnosticsIbex Medical Analytics received CE-IVDR certification for its breast IHC workflow covering ER, PR, and Ki67, completing regulatory approval for its breast portfolio. The certification follows clinical studies and EU review, and the company plans to expand its breast AI pipeline.YahooAI-Powered Imaging Systems and Deep Learning Software Revolutionize Cancer Diagnostics Market GloballyThe AI in cancer diagnostics market is projected to grow from $0.79 billion in 2025 to $0.96 billion in 2026, reaching $1.97 billion by 2030, driven by AI/ML advancements, expanding diagnostic networks, and rising cancer prevalence. Lunit announced the acquisition of Volpara for $193 million, subject to shareholder and court approval, to strengthen AI-driven cancer diagnosis capabilities through Volpara's database and facility presence. Dedalus and Ibex Medical Analytics have launched integrated AI-powered systems in Europe to improve diagnostic accuracy.openPR.comOutlook on the Artificial Intelligence in Cancer Diagnostics Market: Major Segments, Strategic Developments, and Leading CompaniesThe AI in cancer diagnostics market is projected to reach $2.02 billion by 2030, growing at a compound annual growth rate of 30.9%, driven by increased demand for early cancer detection, precision medicine adoption, and AI-powered diagnostic improvements. In July 2025, RadNet Inc. acquired iCAD Inc. to strengthen its cancer screening capabilities with AI-powered breast health technologies. In October 2023, F. Hoffmann-La Roche AG partnered with Israel's Ibex Medical Analytics and Amazon Web Services to deploy AI-driven digital pathology tools for breast and prostate cancer diagnosis.Business Wire BlogIbex Medical Analytics Establishes Biopharma Advisory Board to Advance AI-Powered Precision DiagnosticsIbex Medical Analytics, a leader in AI-powered pathology, announced the formation of a Biopharma Advisory Board to support its expansion into biopharma and biomarker development. The Board includes Ruth March and Paolo Tarantino, who will provide strategic and scientific guidance during the company's growth efforts.PharmiWeb.comIbex Medical Analytics Establishes Biopharma Advisory Board to Advance AI-Powered Precision DiagnosticsIbex Medical Analytics announced the establishment of a Biopharma Advisory Board and appointed Dr. Ruth March and Dr. Paolo Tarantino as its first members to guide the company's strategic expansion into biopharma services. Dr. March joins with a distinguished background at AstraZeneca where she led approval of over 70 companion diagnostics and pioneered ctDNA-guided therapy approvals, while Dr. Tarantino brings expertise in antibody-drug conjugate research as a breast medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School. The advisory board will provide strategic and scientific guidance for AI-driven biomarker development and companion diagnostics, leveraging Ibex's existing clinical network deployed across over 50 health systems to support pharmaceutical partners from early development through global commercialization.PR NewswireDigital Pathology Market to Reach USD 1,791.30 Million by 2030, Growing at 9.3% CAGR: Allied Market ResearchThe global digital pathology market is projected to grow from USD 735.75 million in 2020 to USD 1,791.30 million by 2030, a CAGR of 9.3%. Growth is driven by rising cancer incidence, AI integration, and telepathology adoption, with North America leading and Asia-Pacific growing fastest.openPR.comAnalysis of Segments and Major Growth Areas in the Cancer Biomarker MarketThe global cancer biomarker market is projected to reach $52.63 billion by 2030, growing at a compound annual growth rate of 16.0%, driven by advances in personalized medicine and precision oncology. In a notable development in June 2025, Illumina Inc. acquired SomaLogic Inc. for $350 million, with an additional $75 million contingent on performance milestones, to integrate high-throughput proteomics and biomarker capabilities into its sequencing platform. The market is also seeing AI-driven innovation, exemplified by Ibex Medical Analytics' September 2023 launch of Galen Breast HER2, an AI-enabled platform for improved HER2 scoring in breast cancer patients.Clinical Lab ProductsIbex Medical Analytics Launches Next-Generation AI Pathology PlatformIbex Medical Analytics unveiled Ibex 4, its next-generation AI-powered pathology platform designed to help pathologists manage rising case volumes and diagnostic complexity. The platform expands breast cancer diagnostic capabilities with end-to-end workflows and zero-click immunohistochemistry tools for HER2, ER, PR, and Ki67 markers, with regulatory clearances spanning the US, UK, Australia, Brazil, Israel, and Switzerland. The company will present details and live demonstrations at the 115th United States and Canadian Academy of Pathology Annual Meeting in San Antonio, Texas, March 21–26.Business Wire BlogIbex Medical Analytics Unveils Ibex 4, the Next-Generation AI Platform Setting a New Standard in Comprehensive Cancer Diagnostics and Patient CareIbex Medical Analytics announced the launch of Ibex 4, its next-generation AI platform for clinical-grade cancer pathology diagnostics, designed to alleviate rising case volumes and diagnostic complexity facing pathology departments worldwide. The platform features an end-to-end breast cancer workflow including automated H&E analysis, "zero-click" IHC quantification for HER2, ER, PR, and Ki67 scoring, and an enhanced user interface aimed at improving diagnostic accuracy and lab efficiency. Studies referenced in the announcement demonstrated that Ibex AI identified 57% more patients potentially eligible for targeted HER2 therapy by correcting over half of false HER2 0 classifications, with further evidence to be presented at USCAP 2026.